Navigation Links
Plasma-based treatment goes viral
Date:12/5/2011

Life-threatening viruses such as HIV, SARS, hepatitis and influenza, could soon be combatted in an unusual manner as researchers have demonstrated the effectiveness of plasma for inactivating and preventing the replication of adenoviruses.

When exposed to plasma the fourth state of matter in addition to solids, liquids and gases for a period of just 240 seconds, it was found that only one in a million viruses could still replicate practically all were inactivated.

The study, published in IOP Publishing's Journal of Physics D: Applied Physics, is one of the first to concentrate specifically on viruses and builds on research that has already shown the usefulness of plasma in eradicating bacteria from skin (http://www.iop.org/news/09/november/page_42357.html) and sterilising water (http://www.iop.org/news/11/nov/page_52641.html).

Within a hospital environment, a plasma generating device could realistically rid hands of potentially lethal viruses that relay on a host organism to replicate and spread. In the long-term, plasma could be inhaled directly to treat viruses in the lungs, or applied to blood outside of the body to remove any viruses before transfusion.

The researchers, from the Max-Planck Institut fr extraterrestrische Physik and Technische Universitt Mnchen, specifically chose adenoviruses to examine as they are one of the most difficult viruses to inactivate. Illnesses resulting from this specific virus, for example, can only be managed by treating symptoms and complications of the infection, rather than targeting the actual virus itself.

Adenoviruses predominantly cause respiratory illnesses such as pneumonia and bronchitis and are hard to inactivate as the whole virus is encased in a protein layer, helping it to remain physically stable and tolerate moderate increases in heat and pH.

In this study, the adenoviruses were diluted to specific concentrations and then exposed to plasma for 240 seconds, before being incubated for an hour. A control group of adenoviruses were given the exact same treatment apart from the plasma exposure.

Two separate cell lines were then infected with the two sets of adenoviruses: the ones that were treated with plasma and the control group. To test whether a cell had the virus or not, the researchers programmed the virus to produce a protein that fluoresced green when a specific type of light was shone onto it.

Whilst the exact mechanisms behind the plasma's impressive effects are relatively unknown, it is thought that they are a result of a combination of reactions between the plasma and surrounding air, which create similar species to the ones found in our own immune system when under microbial attack.


'/>"/>
Contact: Michael Bishop
michael.bishop@iop.org
01-179-301-032
Institute of Physics
Source:Eurekalert

Related biology news :

1. Phase I trial begins using gene therapy and bone marrow stem cells in the treatment of brain cancer
2. Novel monoclonal antibody offers potential treatment for tumors resistant to VEGF therapy
3. Fish flu: Genetics approach may lead to treatment
4. Possible treatment target found for main cause of severe liver disease in kids
5. Texas A&M center confronts antibiotic crisis with potential new bacterial treatment
6. Evidence for spinal membrane as a source of stem cells may advance spinal cord treatment
7. Dormant malaria parsites in red blood cells may contribute to treatment failure
8. British study may improve glaucoma assessment and treatment
9. Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases
10. UT Southwestern research could lead to new treatments for IBD, viral infections
11. Cracking breast cancers genetic code may lead to new treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 According to a new report published by ... - 2022," the global biometric sensor market is expected to garner $1.5 billion ... 2015, Asia-Pacific dominated the global market and contributed over ... Continue Reading ... ...
(Date:1/12/2017)... Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... technologies, today announced that it has signed agreements with ... and the Middle East for ... marks the first wave of international distribution agreements for ... blood samples. The initial partners will introduce ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... India , January 24, 2017 According to ... Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, ... to 2021", published by MarketsandMarkets, the global market is expected to reach ... a CAGR of 12.4% from 2016 to 2021. ... ...
(Date:1/24/2017)... 2017  Bruker today announced that it ... in the development, manufacture, and sale of ... innovative nanomechanical testing instruments to Bruker,s existing ... profilometers, and tribology and mechanical testing systems, ... research markets. Hysitron,s 2016 revenues were approximately ...
(Date:1/24/2017)... ... January 24, 2017 , ... Amendia, Inc., designer, developer, ... F. McAllister as Executive Vice President and Chief Financial Officer. , Steve has ... markets. Beginning his career at Howmedica, Inc., he has since served in various ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... available malaria Plasmodium falciparum culture panels with standard concentrations of histidine rich protein ... available in a range of concentrations from six different malaria strains, are intended ...
Breaking Biology Technology: